Researchers from the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during ...

The World Health Organization (WHO) has announced that it has added Pfizer’s maternal respiratory syncytial virus (RSV) vaccine to its list of prequalified vaccines. Abrysvo, which is now the first ...

Just 1 in 10 older adults who participated in the study had received an RSV vaccine during the first season when RSV vaccines were available, from 2023 to 2024, the data showed.

ABRYSVO is the first and only RSV vaccine approved in the European Union ... can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its ...

the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in ...

England’s respiratory syncytial virus (RSV) vaccination programme has achieved a ‘significant’ reduction in hospital admissions among older people, a new study has found. Analysis by the UK Health ...

GSK sued Pfizer in 2023, arguing that the New York-based company's vaccine infringed GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer began working on its RSV program ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts ... described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ...